Viatris reports Q3 2026 earnings, raises 2026 guidance
Viatris reported Q3 revenues of $3.75B and raised its 2026 guidance. The company also received regulatory approvals and announced the planned acquisition of Pacira BioSciences, coupled with $717M in capital returned to shareholders.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed